Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed
Contributed Opinion

Share on Stocktwits


As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative.

Avivagen Inc. (VIV:TSX.V) is an interesting company because it is in the vanguard of the drive to eliminate the non-medicinal use of antibiotics in animal feed, which not only has huge benefits for the animals themselves but for their human consumers because of the alarming spread of antibiotic resistance. Many countries are now banning the use of non-medicinal use of antibiotics in animal feed.

Avivagen is a leading company in the drive to create a safe and effective alternative to antibiotics in animal feed, and to say that this is a massive market is an understatement. As the company says on its website, "In response to this impending global threat (posed by antibiotic resistance), at the consumer level retailers such as McDonald's, Costco and Subway are now sourcing certain meat products raised without the use of antibiotics, and producers such as Cargill and Tyson are planning to reduce or eliminate the use of antibiotics in meat production." So it is easy to comprehend why Avivagen's stock has such huge potential.

Now we proceed to examine the charts for the company's stock. Starting with the long-term 15-year chart, we see that the company has been around for a long time, and clearly, Apple Inc. would have been a better investment up to now. However, this chart reveals that a giant Double Bottom base pattern has formed from 2011 through 2016, and with the price having recently dropped back to the strong support close to the lows of the Double Bottom, thanks to the former CEO or president unwinding his considerable stock position, a process that now looks to be complete, it is clearly very cheap now. So we will now zoom in to see more clearly what has been going on in the recent past on shorter-term charts.

The 3-year chart enables us to see how the price surged out of the Double Bottom in 2016, rising five-fold in a matter of months, but it has since reacted back slowly for two years now to the extent that it has given back virtually all of those gains. In large part this is believed to be due to the former CEO or president unwinding his considerable stock position, as mentioned above, and technically there are signs that this process is complete, which we will see better on the 6-month chart. The two-year downtrend has taken the form of a bullish Falling Wedge, accompanied by a positive volume pattern and volume indicators holding up well all this year and as the Wedge is now closing up, the chances of an upside breakout into a new uptrend are improving rapidly.

The 6-month chart is most interesting as it reveals the inner dynamics of what is now going on. We can see the demand kicking in as the price dug into the support very close to the lows of the big Double Bottom, and this demand has become quite aggressive in recent weeks, causing a number of high volume long-tailed candlesticks to appear, and driving up the Accumulation line. This is a sign of determined accumulation, and with momentum (MACD) starting to swing positive and the falling 200-day moving average closing on the price, we could see a break to the upside soon, and the volume pattern suggests that it will not wait for the 200-day moving average to completely close the gap with the price before it does break out.

With its very positive fundamentals and auspicious technical setup and it being at an excellent entry point at a low level, Avivagen is rated an immediate strong buy. The company has a reasonable 31 million shares in issue. While it does trade on the US OTC market, volumes there are horribly light, so it should not be traded on this market, at least until we see a big improvement in volumes.

Avivagen Inc website.

Avivagen Inc, VIV.V, CHEXF on OTC, closed at C$0.62, $0.40 on 28th September 2018.

Clive Maund has been president of, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.


1) Clive Maund: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None. My company has a financial relationship with the following companies mentioned in this article: None. disclosures below. I determined which companies would be included in this article based on my research and understanding of the sector.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Charts provided by the author. Disclosure:
The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.

Want to read more about Nutraceuticals and Agriculture investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe